HCmed Innovations Co., Ltd.

As of June 30, 2026, HCmed Innovations Co., Ltd. carries a market capitalization of 2.35B, placing it among publicly traded companies globally. Its enterprise value stands at 2.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, HCmed Innovations Co., Ltd. has 36.13M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 20.32, and the price-to-book ratio stands at 4.43.

These figures are as of June 30, 2026. The EV/Sales ratio of 18.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.03B versus a market cap of 2.35B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, HCmed Innovations Co., Ltd. maintains a current ratio of 9.09, meaning it holds 9.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.73, indicating elevated leverage, while an interest coverage ratio of -45.86 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, HCmed Innovations Co., Ltd. posted a negative return on equity (ROE) of -30.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -24.01, reflecting losses generated across the asset base. The company generates approximately 1.79M in revenue per employee across its workforce of 61.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.33 indicates how many times HCmed Innovations Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, HCmed Innovations Co., Ltd. recorded 10,000.00 in income tax expense. The company reported a pretax loss of -124.60M and -124.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, HCmed Innovations Co., Ltd. generated 109.19M in revenue and converted that into -124.61M in net income, yielding earnings per share of -3.65. EBITDA reached -101.76M, while operating income came in at -130.71M.

As of June 30, 2026, HCmed Innovations Co., Ltd. holds 423.89M in cash and equivalents against 104.47M in total debt, resulting in a net debt position of -125.81M. Total book value stands at 529.57M, with working capital of 420.20M providing operational flexibility.

HCmed Innovations Co., Ltd. produced -100.12M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -59.47M in capital expenditures, free cash flow totaled -159.59M - equivalent to -4.68 per share.

Over the twelve months ended June 30, 2026, HCmed Innovations Co., Ltd. posted a gross margin of 10.64, reflecting its pricing power and cost economics. The operating margin of -119.71 and net profit margin of -114.12 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.56, meaning HCmed Innovations Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

HCmed Innovations Co., Ltd.'s most recent stock split took place on February 6, 2025.

As of June 30, 2026, HCmed Innovations Co., Ltd. has an Altman Z-Score of 8.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.